Martin R Sprick
Martin R Sprick
HI-STEM gGmbH, DKFZ-Heidelberg
Bestätigte E-Mail-Adresse bei dkfz.de - Startseite
Titel
Zitiert von
Zitiert von
Jahr
Wnt activity defines colon cancer stem cells and is regulated by the microenvironment
L Vermeulen, EM Felipe De Sousa, M Van Der Heijden, K Cameron, ...
Nature cell biology 12 (5), 468-476, 2010
17192010
FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2
MR Sprick, MA Weigand, E Rieser, CT Rauch, P Juo, J Blenis, ...
Immunity 12 (6), 599-609, 2000
9542000
Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay
I Baccelli, A Schneeweiss, S Riethdorf, A Stenzinger, A Schillert, V Vogel, ...
Nature biotechnology 31 (6), 539-544, 2013
8772013
Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity
L Vermeulen, M Todaro, F de Sousa Mello, MR Sprick, K Kemper, ...
Proceedings of the National Academy of Sciences 105 (36), 13427-13432, 2008
7912008
Caspase‐10 is recruited to and activated at the native TRAIL and CD95 death‐inducing signalling complexes in a FADD‐dependent manner but can not functionally substitute caspase‐8
MR Sprick, E Rieser, H Stahl, A Grosse‐Wilde, MA Weigand, H Walczak
The EMBO journal 21 (17), 4520-4530, 2002
4682002
Cancer stem cells–old concepts, new insights
L Vermeulen, MR Sprick, K Kemper, G Stassi, JP Medema
Cell Death & Differentiation 15 (6), 947-958, 2008
3942008
The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation
K Kemper, MR Sprick, M de Bree, A Scopelliti, L Vermeulen, M Hoek, ...
Cancer research 70 (2), 719-729, 2010
3822010
The interplay between the Bcl-2 family and death receptor-mediated apoptosis
MR Sprick, H Walczak
Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1644 (2-3), 125-132, 2004
2992004
Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by …
TM Ganten, TL Haas, J Sykora, H Stahl, MR Sprick, SC Fas, A Krueger, ...
Cell Death & Differentiation 11 (1), S86-S96, 2004
2452004
Proteasome Inhibition Results in TRAIL Sensitization of Primary Keratinocytes by Removing the Resistance-Mediating Block of Effector Caspase Maturation
M Leverkus, MR Sprick, T Wachter, T Mengling, B Baumann, E Serfling, ...
Molecular and Cellular Biology 23 (3), 777-790, 2003
1462003
Oncogenic K-Ras turns death receptors into metastasis-promoting receptors in human and mouse colorectal cancer cells
FJH Hoogwater, MW Nijkamp, N Smakman, EJA Steller, BL Emmink, ...
Gastroenterology 138 (7), 2357-2367, 2010
1362010
CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma
EM Noll, C Eisen, A Stenzinger, E Espinet, A Muckenhuber, C Klein, ...
Nature medicine 22 (3), 278-287, 2016
1352016
TNF-related apoptosis-inducing ligand mediates tumoricidal activity of human monocytes stimulated by Newcastle disease virus
B Washburn, MA Weigand, A Grosse-Wilde, M Janke, H Stahl, E Rieser, ...
The Journal of Immunology 170 (4), 1814-1821, 2003
1332003
Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL-and CD95L-mediated apoptosis
P Geserick, C Drewniok, M Hupe, TL Haas, P Diessenbacher, MR Sprick, ...
Oncogene 27 (22), 3211-3220, 2008
1312008
Bortezomib Sensitizes Primary Human Astrocytoma Cells of WHO Grades I to IV for Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis
R Koschny, H Holland, J Sykora, TL Haas, MR Sprick, TM Ganten, ...
Clinical Cancer Research 13 (11), 3403-3412, 2007
1282007
TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer‐specific apoptosis within a therapeutic window
R Koschny, TM Ganten, J Sykora, TL Haas, MR Sprick, A Kolb, ...
Hepatology 45 (3), 649-658, 2007
1282007
Biochemistry and function of the DISC.
H Walczak, MR Sprick
Trends in biochemical sciences 26 (7), 452-453, 2001
962001
Screening drug effects in patient‐derived cancer cells links organoid responses to genome alterations
J Jabs, FM Zickgraf, J Park, S Wagner, X Jiang, K Jechow, K Kleinheinz, ...
Molecular systems biology 13 (11), 955, 2017
952017
A synergistic interaction between Chk1-and MK2 inhibitors in KRAS-mutant cancer
F Dietlein, B Kalb, M Jokic, EM Noll, A Strong, L Tharun, L Ozretić, ...
Cell 162 (1), 146-159, 2015
942015
MicroRNA-31 initiates lung tumorigenesis and promotes mutant KRAS-driven lung cancer
MD Edmonds, KL Boyd, T Moyo, R Mitra, R Duszynski, MP Arrate, X Chen, ...
The Journal of clinical investigation 126 (1), 349-364, 2016
93*2016
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20